MedTrace Logo

Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease

NCT01018264 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2021-11-09

Study results available
· View outcomes & findings →

Summary

This study will assess the effectiveness of solifenacin succinate (VESIcare) in reducing symptoms of overactive bladder in Parkinson's disease (PD) patients.

Conditions

  • Overactive Bladder in Parkinson's Disease

Interventions

DRUG

solifenacin succinate (VESIcare)

up to 10mg every day orally

DRUG

placebo

placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day

Sponsors & Collaborators

  • University of South Florida

    lead OTHER

Principal Investigators

  • Theresa Zesiewicz, MD · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01018264 on ClinicalTrials.gov